Cargando…
In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate
OBJECTIVE(S): In this study, Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobody was fabricated in which nanobody was selected for blocking the receptor, H40 as a nanocarrier for delivery of methotrexate (MTX) to the tumor cells, and polyethylene glycol (PEG) moieties for improving the blood circulation time...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mashhad University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742571/ https://www.ncbi.nlm.nih.gov/pubmed/36544521 http://dx.doi.org/10.22038/IJBMS.2022.67038.14701 |
_version_ | 1784848551046545408 |
---|---|
author | Adyani, Seyed Masih Rashidzadeh, Hamid Behdani, Mahdi Tabatabaei Rezaei, Seyed Jamal Ramazani, Ali |
author_facet | Adyani, Seyed Masih Rashidzadeh, Hamid Behdani, Mahdi Tabatabaei Rezaei, Seyed Jamal Ramazani, Ali |
author_sort | Adyani, Seyed Masih |
collection | PubMed |
description | OBJECTIVE(S): In this study, Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobody was fabricated in which nanobody was selected for blocking the receptor, H40 as a nanocarrier for delivery of methotrexate (MTX) to the tumor cells, and polyethylene glycol (PEG) moieties for improving the blood circulation time and safety. MATERIALS AND METHODS: The synthesis process of the nanosystem has been characterized by different analytical methods. RESULTS: The prepared nanoplatform exhibited high drug loading capacity, excellent colloidal stability, and an average particle size of around 105 nm. MTX was successfully conjugated through ester bonds and its release profile clearly showed that the ester bond is in favor of releasing the drug in acidic pH (5.5). The cytotoxicity of the developed nanoplatform exhibited great anti-cancer activity against MCF7 and KDR293 (cells with overexpressed anti-VEGFR2 NB receptors) cell lines while no deleterious toxicity was observed for nanocarrier against HEK293 normal cells. Furthermore, both hemolysis and LD(50) assay results confirmed the hemocompatibility and biocompatibility of the developed nanoplatform. CONCLUSION: The most striking result to derive from the data is that the designed nanoplatform could potentially inhibit cell migration and invasion and the anti-angiogenesis properties of the developed nanoplatform may serve as a promising nanosystem to suppress the formation of blood vessels around tumor cells and consequently inhibit tumor progression. |
format | Online Article Text |
id | pubmed-9742571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Mashhad University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-97425712022-12-20 In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate Adyani, Seyed Masih Rashidzadeh, Hamid Behdani, Mahdi Tabatabaei Rezaei, Seyed Jamal Ramazani, Ali Iran J Basic Med Sci Original Article OBJECTIVE(S): In this study, Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobody was fabricated in which nanobody was selected for blocking the receptor, H40 as a nanocarrier for delivery of methotrexate (MTX) to the tumor cells, and polyethylene glycol (PEG) moieties for improving the blood circulation time and safety. MATERIALS AND METHODS: The synthesis process of the nanosystem has been characterized by different analytical methods. RESULTS: The prepared nanoplatform exhibited high drug loading capacity, excellent colloidal stability, and an average particle size of around 105 nm. MTX was successfully conjugated through ester bonds and its release profile clearly showed that the ester bond is in favor of releasing the drug in acidic pH (5.5). The cytotoxicity of the developed nanoplatform exhibited great anti-cancer activity against MCF7 and KDR293 (cells with overexpressed anti-VEGFR2 NB receptors) cell lines while no deleterious toxicity was observed for nanocarrier against HEK293 normal cells. Furthermore, both hemolysis and LD(50) assay results confirmed the hemocompatibility and biocompatibility of the developed nanoplatform. CONCLUSION: The most striking result to derive from the data is that the designed nanoplatform could potentially inhibit cell migration and invasion and the anti-angiogenesis properties of the developed nanoplatform may serve as a promising nanosystem to suppress the formation of blood vessels around tumor cells and consequently inhibit tumor progression. Mashhad University of Medical Sciences 2022-12 /pmc/articles/PMC9742571/ /pubmed/36544521 http://dx.doi.org/10.22038/IJBMS.2022.67038.14701 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Adyani, Seyed Masih Rashidzadeh, Hamid Behdani, Mahdi Tabatabaei Rezaei, Seyed Jamal Ramazani, Ali In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
title |
In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
title_full |
In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
title_fullStr |
In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
title_full_unstemmed |
In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
title_short |
In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
title_sort | in vitro evaluation of anti-angiogenesis property of anti-vegfr2 nanobody-conjugated h40-peg carrier loaded with methotrexate |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742571/ https://www.ncbi.nlm.nih.gov/pubmed/36544521 http://dx.doi.org/10.22038/IJBMS.2022.67038.14701 |
work_keys_str_mv | AT adyaniseyedmasih invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate AT rashidzadehhamid invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate AT behdanimahdi invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate AT tabatabaeirezaeiseyedjamal invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate AT ramazaniali invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate |